JP2003171288A - Leucocyte-removed blood product, method for producing the same and formulation set for the same - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To obtain a blood product for blood transfusion capable of being preserved in a safer state for a long time, provide a method for producing the same and provide a set of blood products for the same. <P>SOLUTION: This leucocyte-removed blood product is prepared by holding at least one component out of blood components separated by using the set of blood products in blood component bags made of a vinyl chloride resin containing a citric acid ester-based plasticizer. In the set of the blood products, a leucocyte-removing filter is connected with a blood-collecting bag and several blood component bags are connected to the filter. The set of blood products and the method for producing the blood product are provided. <P>COPYRIGHT: (C)2003,JPO

Description

Detailed Description of the Invention

[0001]

TECHNICAL FIELD The present invention relates to a leukocyte-removed blood preparation, a method for producing the same, and a set of preparations therefor.

[0002]

2. Description of the Related Art Currently, for blood transfusion, there is a method of separating blood obtained from a donor into respective components by centrifugal force and storing them in separate containers for the purpose of effectively using the blood and reducing the burden on the transfused person. Has been taken. Blood components conventionally separated in this way,
Especially for storing red blood cell preparations, phthalate plasticizers,
Particularly, a container made of vinyl chloride resin (hereinafter sometimes referred to as vinyl chloride) plasticized with di-2-ethylhexyl phthalate (DEHP) is used.

[0003] Certain phthalates are excellent plasticizers and also stabilize red blood cell membranes during storage of red blood cell preparations, and suppress red blood cell deterioration during storage, especially hemolysis and cell morphological changes. It is known to have an action. (Reference: Blood, 1984, pp1270)

On the other hand, in recent years, the toxicity of plasticizers eluted in red blood cells has become a major concern. In particular, it has been confirmed that DEHP, which has been used as a plasticizer for PVC from the past, is a liver carcinogen in rodents, and in recent years, DEHP, which has been transferred into the living body through oral or intravenous administration, reduces sperm count. It was reported that there was a risk of induction.

In order to solve these problems, a vinyl chloride blood bag and a polyolefin blood bag using a non-eluting plasticizer such as trimellitic acid ester, especially trioctyl trimellitate (TOTM), instead of DEHP, have been studied. However, it was not possible to store the red blood cell product for a long period of time because of significant hemolysis in the separated blood components, especially the red blood cell product.

[0006] Further, vinyl chloride blood storage bags containing a citrate ester such as acetyl tri-n-butyl citrate (ATBC) as a plasticizer were also examined, but red blood cells were stored for a long time in these bags. In some cases, more than 1% significant hemolysis occurred. Also, in a PVC blood storage bag containing a certain type of citrate ester as a plasticizer,
The stored red blood cells undergo morphological changes.

Apart from the blood bag, in order to suppress the deterioration of red blood cells in the red blood cell preparation, certain vitamins such as cartinin and vitamin E (Transfu
sion, 1997, pp166) and the addition of high molecular weight saccharides are considered, but it is expected that this kind of drug is susceptible to decomposition and inactivation during sterilization at high temperature. Thus, a red blood cell preparation that can be stored safely for a long period of time is particularly desired.

[0008]

An object of the present invention is to provide a blood transfusion product which can be stored in a safer state for a long period of time, a method for producing the same, and a set of preparations therefor.

[0009]

For example, when a red blood cell preparation for blood transfusion is stored for a long period of time, hemolysis of red blood cells occurs. Physical causes such as temperature change, contact with the bag surface, and stored blood are the causes. Chemical factors due to coexisting components are considered. Above all, it is considered that the influence of peroxidative substances released by coexisting leukocytes is great.

The inventor of the present invention eliminates hemolysis of erythrocytes by removing the white blood cells from the blood components before containing them and then separating the blood components and storing the separated blood components in a container with high safety for the living body. The inventors have found that it is possible to significantly improve the safety of blood products for blood transfusion, and have reached the present invention.

That is, the erythrocyte preparation for transfusion that can be stored for a long period of time is a blood component separated from the leukocyte existing in the blood before being stored by a filter incorporated in the blood preparation set and then centrifuged to separate the separated blood component, particularly It became possible to store the red blood cell component in a vinyl chloride bag that does not contain DEHP, which is likely to affect the living body.

In the first aspect of the present invention, a leukocyte removal filter is connected to a blood collection bag, and a plurality of blood component bags are connected to the leukocyte removal filter, and at least one of the blood component bags is a citrate ester plasticizer. Using a blood product set made of a vinyl chloride resin containing, the blood from which white blood cells have been substantially removed is stored in a blood component bag made of a vinyl chloride resin containing the citrate plasticizer. Is a leukocyte-removed blood product.

In a preferred first aspect of the present invention, the blood substantially free of leukocytes is separated by centrifugal force, and red blood cells among the blood components obtained are vinyl chloride containing the citrate plasticizer. This is a leukocyte-removed blood product contained in a resin blood component bag.

It is preferable that the other bag except at least one of the blood component bags is a vinyl chloride resin bag containing a citrate ester plasticizer or a trimellitic acid ester plasticizer.

It is preferable that the citric acid ester plasticizer is represented by the general formula 1 (wherein R ₁ represents an acetyl group or a butyryl group, and R ₂ represents an alkyl group having 3 to 8 carbon atoms). .

[Formula 2]

The citric acid ester plasticizer is preferably acetyl citric acid trialkyl ester or butyryl citric acid trialkyl ester.

The acetyl citrate trialkyl ester is acetyl citrate tri-n-butyl (ATB
C), tri-n-hexyl acetyl citrate (ATH
C) and triethylhexyl acetylcitrate (AT
It is preferably at least one selected from the group consisting of EHC).

The butyryl citrate trialkyl ester is butyryl citrate tri-n-hexyl (BTH
C) is preferred.

At least one of the blood component bags is
It is preferable that the red blood cell preservation solution is enclosed.

In a second aspect of the present invention, the blood collected in advance in a blood collection bag is passed through a leukocyte removal filter to remove leukocytes, and the obtained blood containing substantially no leukocytes is citrate ester plasticizer. A method for producing a leukocyte-removed blood product, which comprises encapsulating in a vinyl chloride resin blood component bag containing

The blood containing substantially no white blood cells is separated by centrifugal force, and among the separated blood components, red blood cells are separately sealed in a vinyl chloride resin blood component bag containing the citrate plasticizer. It is preferable.

A third aspect of the present invention is a blood product set comprising a blood collection bag, a leukocyte removal filter connected to the blood collection bag, and a plurality of blood component bags connected to the leukocyte removal filter, At least one of the component bags is a vinyl chloride resin bag containing a citric acid ester plasticizer, which is a leukocyte-removing blood product set.

The blood collection bag is preferably a vinyl chloride resin bag or a polyolefin bag containing a plasticizer different from the plasticizer contained in the blood component bag.

[0024]

BEST MODE FOR CARRYING OUT THE INVENTION The leukocyte-removed blood product of the present invention comprises:
A blood collection bag is connected to the upstream side of the filter intended to remove leukocytes in the blood, and at least three types of blood component bags are connected to the downstream side of the leukocyte removal filter.
In a leukocyte-removing blood product set which is aseptically connected by a tube, the component bag is prepared by using a vinyl chloride bag containing a citrate ester plasticizer. That is, the blood product of the present invention removes leukocytes from the blood collected in the blood collection bag of the set through the filter and then performs centrifugation to separate the blood component separated by the difference in specific gravity into the blood component bag. It is manufactured by separately packaging. Here, the leukocyte removal filter may be one that captures platelets at the same time as leukocytes.

The blood collecting bag of the present invention comprises 60 to 80 parts by mass of TOTM and di-n phthalate per 100 parts by mass of vinyl chloride.
A non-eluting plasticizer such as decyl (DnDP), a vinyl chloride resin added with 45 to 65 parts by mass of a citrate ester plasticizer, or a non-vinyl chloride soft polymer such as polyolefin or polyurethane.
Inside the bag, ACD (acid citrate dextrose), CPD (citrate phosphate,
An anticoagulant such as dextrose) is encapsulated.

A blood collection tube having a blood collection needle is connected to the bag. Similar to the blood collection bag, the blood collection tube is made of a vinyl chloride resin plasticized with a non-eluting plasticizer or a citrate ester plasticizer, or a non-vinyl chloride soft polymer such as polyolefin or urethane.

The leukocyte-removing filter of the present invention is a filter whose purpose is to capture leukocytes in blood, and removes most leukocytes and platelets contained in blood. In order to achieve this object, any of a fibrous material, a woven cloth, a non-woven cloth, a porous material, a filter filled with a particulate matter and the like can be used. The material of the filter may be either a hydrophilic material or a hydrophobic material.

The blood component bag of the present invention is a liquid-tight bag used for separating and storing whole blood into concentrated red blood cells and plasma, and its material is plasticized with a plasticizer as in the blood collection bag. Vinyl chloride resin or a vinyl chloride resin plasticized with a non-eluting plasticizer. As the citric acid ester plasticizer, the one represented by the general formula 1 is used.

[Formula 3] (In the formula, R ₁ represents an acetyl group or a butyryl group, and R ₂ represents an alkyl group having 3 to 8 carbon atoms.)

Specifically, acetylcitrate tri-n-
Butyl (ATBC), acetyl citrate tri-n-hexyl (ATHC), acetyl citrate triethylhexyl (ATEHC) and other acetyl citrate trialkyl esters, and butyryl citrate tri-n-hexyl (B
THC), butyryl citrate triethylhexyl (BT
Butyryl citrate trialkyl esters such as EHC) are preferred. Further, examples of the non-hemolytic plasticizer include trioctyl trimellitate (TOTM), di-n-decyl phthalate (DnDP) and diundecyl phthalate (DUP).

Representative examples of the leukocyte-removed blood product set and the method for producing a blood product of the present invention will be described in more detail below with reference to the drawings.

Blood collected from the donor is the blood collection bag 1
And is mixed with the anticoagulant present in the blood collection bag. This prevents blood coagulation. The anticoagulated blood is sent to the leukocyte removal filter 2 through the connecting tube by gravity or by a method such as pressing a blood collection bag. The leukocyte depletion filter removes the majority of leukocytes and platelets. The blood passing through the filter is sent to the first blood component bag 3 through the connecting tube, and the blood consists of red blood cells and plasma.

Thereafter, the connecting tube between the leukocyte removal filter 2 and the first blood component bag 3 is pressure-bonded with an aluminum ring or heat-sealed with a heat sealer, and then the blood component bags 3 to 5 are separated from the filter. Only the blood component bags 3 to 5 are bundled and subjected to a centrifugal separator to separate the blood in the blood component bag 3. Thereby, the blood in the first blood component bag 3 is separated into layers, and plasma is accumulated in the supernatant and concentrated red blood cells are accumulated in the lower layer.

Then, the supernatant in the first blood component bag 3 is transferred to the second blood component bag 4, and the first blood component bag 3
The red blood cell preservation solution that had been pre-sealed in the blood component bag 5 was added to the concentrated red blood cells remaining in the above. As the red blood cell preservation solution, a physiological solution containing one or more kinds of adenine, mannitol, sorbitol, guanosine and the like is preferably used.
By adding the erythrocyte preservation solution to the concentrated erythrocytes, the erythrocytes can be stored for a longer period of time and can be used for blood transfusion.

As described above, the second plasma-enclosed second
The blood component bag 4 and the first blood component bag 3 in which the concentrated red blood cells containing red blood cell preservation solution are sealed are commercialized as a preserved blood product for transfusion.

[0035]

The present invention will be described in more detail with reference to the following examples, but the present invention is not limited to these examples.

(Examples 1 to 6 and Comparative Examples 1 to 5) (Manufacture of Bag and Assembly of Preparation Set) A thermoplastic resin sheet (thickness: 390 μm) containing the plasticizer shown in Table 1 in the composition shown in Table 1. ) Were piled up and cut, and the peripheral portion was heat-sealed to prepare a blood collection bag (volume: 200 mL). Also, a blood component bag was produced in the same manner.

[0037]

[Table 1]

50 mL of a red blood cell preservation solution (MAP solution) was dispensed through a tube in the blood component bag, and each component bag was connected with a reversible tube, and a leukocyte removal filter was connected between the blood collection bag and the separation bag. . The filter is composed of a porous body made of polyurethane.

A blood collection tube was connected to the blood collection bag, 30 mL of the anticoagulant (ACD solution) was dispensed through the tube,
The formulation set was assembled. Next, the formulation set was subjected to high-pressure steam sterilization (121 ° C., 30 min). The constituent materials of each bag in the formulation set are shown in Table 2.

[0040]

[Table 2]

(Separation of Blood Components) (Preparation of Specimen of Example) Blood sampled (200 mL) was passed through a leukocyte depletion filter to obtain leukocyte depleted whole blood. According to the standard method (Journal of the Transfusion Society, 1991, pp404), white blood that had been whitened was centrifuged and separated into red blood cell concentrate and plasma. The separated plasma is separated into a plasma bag (bag 4 in Fig. 1), and a red blood cell preservation solution is added to the remaining red blood cell concentrate to add M
AP enriched red blood cells were prepared.

(Preparation of Sample of Comparative Example) The collected whole blood was centrifuged in the same manner as above to separate the plasma and the buffer coat layer. The separated plasma and buffy coat layer were respectively transferred to blood component bags, and MAP solution was added to the remaining concentrated red blood cell concentrate to prepare MAP-enriched red blood cells. The MAP-enriched red blood cells obtained were placed in a low-temperature refrigerator at 4 to 6 ° C for 6 minutes.
It was stored statically for a week. The separated plasma was frozen and stored in a freezer at -20 ° C.

(Blood Preservation Performance Evaluation Test) (Confirmation of Hemolysis Level) The MAP-concentrated erythrocyte-enclosed bag was stored for 21 days and 42 days, and 1 mL of sample blood was aseptically taken from the sample of the example and the sample of the comparative example and taken out The hemoglobin concentration and hematocrit value in each sample were measured with an automatic blood cell counter (SE-9000, Sysmex).

The sample was centrifuged at 1500 G for 10 minutes with a centrifuge (RL-100, TOMY Seiko Co., Ltd.) to collect the plasma of the supernatant, and the leuco crystal violet method (LCV method) was used.
The hemoglobin concentration in the plasma was measured. The measured value obtained as described above was substituted into the following equation to calculate the hemolysis rate.

[0045]

[Equation 1]

(Red blood cell morphology) The MAP-enriched red blood cell-sealed bag was stored for 21 days and 42 days, and 10 μL of blood was taken from the blood aseptically separated from Examples and Comparative Examples, and 1% by mass of glutaraldehyde. With 0.1
The cells were placed in an M cacodylate buffer (pH 7.4) and allowed to stand overnight in a constant temperature bath at 4 ° C. to fix red blood cells.

Erythrocyte cells fixed with glutaraldehyde were attached to a glass plate, platinum vapor deposition treatment was performed, and 300 red blood cells were observed with a scanning electron microscope (JSM-840, JEOL). Longster et al. Method (Vox sang, 1972, pp16
Classify the morphology of red blood cells according to 1), multiply each coefficient according to each morphology, divide the sum by 3, and divide by 10 cells.
Red blood cell morphology value (Morphological S
core).

(ATP concentration) The day 0 and MAP-enriched erythrocyte-enclosed bags were stored for 21 days and 42 days, and 1 mL of sample blood was aseptically taken from the sample of the example and the sample of the comparative example and taken out. The ATP concentration therein was measured by an enzymatic method using a commercially available measurement kit (ATP test, Sigma). The ATP concentration on the 21st and 42nd days of storage is
The TP concentration was expressed as a relative amount with 100%.

(Glucose consumption) Day 0 and MAP
Store the concentrated red blood cell enclosed bag for 21 days, 42 days,
Blood samples were taken aseptically from the samples of Examples and Comparative Examples, and the glucose concentration in the taken samples was measured with a commercially available kit (Glucose Test Wako, Wako Pure Chemical Industries, Ltd.). The obtained glucose concentration was divided by the hemoglobin concentration in the sample, and the amount of change from day 0 was taken as the glucose consumption amount.

(Lactate concentration) Day 0 and the MAP-enriched red blood cell-encapsulated bag were stored for 21 days and 42 days, and sample blood was aseptically taken from the sample of the example and the sample of the comparative example.
Use the commercially available kit (F-
Test lactic acid, Boehringer Mannheim).
The obtained lactic acid concentration was divided by the hemoglobin concentration in the sample, and the amount of change from day 0 was defined as the lactic acid production amount.

(Elution amount of plasticizer) <Red blood cell preparation> 42
After being stored for 1 day, 1 mL of blood was aseptically separated from the sample of the example and the sample of the comparative example. Isopropyl alcohol was added to this to precipitate the protein in blood, chloroform was added to extract the plasticizer, and the concentration of each plasticizer was quantified by gas chromatography.

<Plasma preparation> After separation, plasma was stored at room temperature for 12 hours, and after cryopreservation for 30 days, it was heated at 37 ° C for 1 hour, and a sample was taken from the plasma after dissolution and eluted into plasma like the red blood cell preparation. The amount of plasticizer added was quantified.

(Safety test) <Oral toxicity> After suspending a plasticizer with Tween 80 (polyoxyethylene sorbitan monooleate) at a concentration of 5% by weight, 2
% (W / w) was mixed with the powdered diet, and 7-week-old rats were fed for 4 days. As a control, a rat fed with a diet containing only Tween 80 was used. After decapitation, the liver was removed, the weight was measured, homogenate was prepared using 3 times the volume of buffer solution, and the homogenate was centrifuged at 2500 rpm for 5 minutes, and the supernatant was used as the measurement sample.

Electrophoresis was carried out using a polyacrylamide gel, and the density of a band corresponding to a detoxification-related enzyme protein corresponding to a molecular weight of 77 kDa was measured with a densitometer to give a powdered diet in which only Tween 80 was suspended. Control example 1
It was expressed as a ratio of 00%. Moreover, the liver weight to 100 g of body weight was defined as the liver mass ratio.

<Cytotoxicity> A plasticizer-added sheet (3.0 g) extracted with 30 mL of MEM medium supplemented with bovine serum at 37 ° C. for 24 hours was used as a sample, and L was collected so as to give about 50 colonies after culturing.
1 mL of the test solution was placed in the well in which 929 cells were seeded, and the cells were cultured in a carbon dioxide incubator at 37 ° C. for 7 days, and the number of appearing colonies was counted. The validity of the test was confirmed by simultaneously performing a blank test (medium only) and positive and negative controls. The colony formation rate (%) was calculated from the ratio of the number of sample colonies to the number of blank test colonies.

<Estrogen-binding property> Each plasticizer was suspended in dimethylsulfoxide (DMSO), DMSO was used to prepare a dilution series, and the estrogen-binding property was evaluated using a commercially available measurement kit.

(Evaluation of Physical Properties) <Flexibility> A melt-pressed sheet is molded, and JIS K72 is used.
The surface hardness (A hardness) was measured according to 15.

<Strength> A melt press sheet is molded and
Tensile strength was measured according to SK7113. The test piece was a No. 2 type test piece, the test speed was 200 mm / min, and the tester was Autograph AGS-110A (manufactured by Shimadzu Corporation).

<Evaluation Results> MAP-enriched red blood cell preservation performance evaluation tests shown in Tables 3 to 4, plasticizer elution amount in plasma shown in Table 5, and safety and physical property test results of each plasticizer shown in Table 6. Therefore, the blood product of the present invention and the method for producing the same are summarized as follows. As a result of the blood preservation performance test shown in Tables 3 to 4 and comparison with Examples 1 to 4 and Comparative Examples 3 to 5,
The hemolysis rate in red blood cells stored in a vinyl chloride bag plasticized with a citric acid ester plasticizer was low for all citric acid ester plasticizers by removing leukocytes before storage.

As a result of the safety evaluation test shown in Table 6, the ratio of the oral toxicity of the phthalate ester plasticizer to the liver mass ratio and the amount of detoxification enzyme expression were found to be other citrate ester plasticizers and trimellitic acid ester plasticizers. It was higher. Regarding the estrogen-binding ability, the phthalate ester-based plasticizer and the trimellitic acid ester-based plasticizer showed the binding ability, whereas the citrate ester-based plasticizer did not show the binding ability. From the above, it became clear that the safety of the citric acid ester plasticizer is higher than that of the phthalic acid ester plasticizer and the trimellitic acid ester plasticizer. As a result of the evaluation of physical properties shown in Table 5, all the A hardness values were 78 to 83, which were about the same, and it was found that the material has sufficient flexibility as a material for the blood bag. Further, it was found that the tensile strengths were all 20 MPa or more, and that they could sufficiently withstand the use of centrifugation as a blood bag.

From the results of the vinyl chloride bag (Example 5) and the polyolefin bag (Example 6) using non-eluting plasticizer trioctyl trimellitate (TOTM) as the blood collection bag, the above evaluation results are as follows: Similar effects were obtained when a vinyl chloride or non-vinyl chloride polymer material containing no eluent plasticizer was used as the blood collection bag.

Further, from the results of Table 5 in which the amount of the plasticizer eluted in the plasma was quantified, comparison was made between Example 5 and Example 1 in which the trimellitic acid ester plasticizer was used as the plasticizer of the plasma storage bag. By using a trimellitic acid ester plasticizer as a plasticizer added to the blood plasma storage bag, it is possible to further suppress the elution of unnecessary plasticizer into plasma components and improve the safety of blood products. It was

As a result of the MAP concentrated erythrocyte preservative test shown in Table 3, comparison between Examples 1 to 3 and 4 shows that trialkyl acetyl citrate was used as the citrate ester plasticizer to preserve the stored erythrocytes. It is clear that the cell morphology can be better maintained.

As a result of the MAP concentrated erythrocyte preservative test shown in Table 3, comparison with Examples 1 and 2 and Example 3 revealed that among the acetyl tricitrate esters, particularly n-alkyl esters were used for storage. Hemolyzed was preserved under lower conditions.

As a result of the MAP concentrated erythrocyte preservative test shown in Table 3, comparison with Examples 1 and 2 and Example 3 revealed that among acetyl tricitric acid esters, particularly n-alkyl ester was used for preservation. The red blood cells could be stored under the condition that the elution of the plasticizer into the red blood cells was small.

As a result of the MAP concentrated erythrocyte storage performance test shown in Table 3, comparison with Example 1 and Example 2 revealed that n-
By using acetyltri-n-hexyl citrate (ATHC) among the alkyl esters, it was possible to suppress hemolysis of the stored red blood cell preparation.

As a result of the MAP concentrated erythrocyte storage performance test shown in Table 3, the hemolysis rate of stored erythrocytes could be suppressed by using trihexyl citrate, especially tri-n-hexyl butyryl citrate (BTHC).

[Table 3]

[Table 4]

[Table 5]

[Table 6]

[0068]

As is apparent from the above, the present invention in which a blood product obtained by removing leukocytes prior to storage, particularly an erythrocyte product, is enclosed and stored in a vinyl chloride bag containing a citrate plasticizer In the case of using, a vinyl chloride bag containing a phthalate plasticizer is used, or a blood product prepared without leukocyte removal is enclosed in a vinyl chloride bag containing a citrate plasticizer and stored. It is a method of preserving a blood product for transfusion that has higher safety to the living body and less damage to the blood product during storage as compared with the case of

These effects are similarly observed by using, as a blood collection bag, a vinyl chloride plasticized with a non-eluting plasticizer such as trioctyl trimellitate or a non-vinyl chloride polymer such as a polyolefin.
By using a non-eluting plasticizer such as trimellitic acid ester as a bag for storing plasma, it is possible to further reduce the amount of plasticizer mixed in the plasma product without impairing the preservability of the red blood cell product. Therefore, it is considered to be a method that contributes to improving the safety of blood products for transfusion.

[Brief description of drawings]

FIG. 1 is a conceptual diagram of a preparation set of the leukocyte-removed blood preparation of the present invention.

[Explanation of symbols]

1: Blood collection bag 2: Leukocyte removal filter 3-5: Blood component bag

─────────────────────────────────────────────────── ─── Continuation of front page (51) Int.Cl. ⁷ Identification code FI theme code (reference) A61P 7/00 A61J 1/00 331B 331A F term (reference) 4C077 AA12 BB02 BB03 BB04 CC04 DD13 KK01 NN02 PP08 PP21 4C087 AA01 AA05 DA04 DA18 MA16 MA66 NA03 ZA51

Claims (12)

[Claims] 1. A blood-collecting bag connected to a leukocyte-removing filter, and a plurality of blood-component bags connected to the leukocyte-removing filter, wherein at least one of the blood-component bags contains a citrate ester plasticizer. Using a blood product set made of a resin, the blood from which white blood cells have been substantially removed is stored in a vinyl chloride resin blood component bag containing the citrate plasticizer, Removed blood products. 2. The blood from which the white blood cells have been substantially removed is separated by centrifugal force, and red blood cells among the blood components obtained are
The leukocyte-removed blood product according to claim 1, which is housed in a vinyl chloride resin blood component bag containing the citrate plasticizer. 3. The bag other than at least one of the blood component bags is a vinyl chloride resin bag containing a citric acid ester plasticizer or a trimellitic acid ester plasticizer. The leukocyte-removed blood product described. 4. The citric acid ester plasticizer is represented by the general formula 1 (wherein R ₁ represents an acetyl group or a butyryl group, and R ₂ represents an alkyl group having 3 to 8 carbon atoms). Item 4. The leukocyte-removed blood product according to any one of Items 1 to 3. [Formula 1] 5. The leukocyte-removing blood product according to claim 1, wherein the citric acid ester plasticizer is acetyl citric acid trialkyl ester or butyryl citric acid trialkyl ester. 6. The acetyl citric acid trialkyl ester is at least one selected from the group consisting of acetyl citrate tri-n-butyl, acetyl citrate tri-n-hexyl and acetyl citrate triethylhexyl. The leukocyte-removed blood preparation according to 5. 7. The leukocyte-removed blood product according to claim 5, wherein the butyryl citrate trialkyl ester is butyryl citrate tri-n-hexyl. 8. At least one of the blood component bags comprises:
The leukocyte-removed blood product according to any one of claims 1 to 7, wherein a red blood cell preservation solution is enclosed. 9. Blood collected in advance in a blood collection bag is passed through a leukocyte removal filter to remove leukocytes, and the obtained blood containing substantially no leukocytes is vinyl chloride containing a citrate plasticizer. A method for producing a leukocyte-removed blood product, characterized by encapsulating in a resin blood component bag. 10. The blood containing substantially no white blood cells is separated by centrifugal force, and among the separated blood components, red blood cells are separated into a vinyl chloride resin blood component bag containing the citrate ester plasticizer. The method for producing a leukocyte-removed blood product according to claim 9, which is encapsulated. 11. A blood product set comprising a blood collection bag, a leukocyte removal filter connected to the blood collection bag, and a plurality of blood component bags connected to the leukocyte removal filter, wherein at least one of the blood component bags is provided. Is a bag made of vinyl chloride resin containing a citric acid ester plasticizer, and a leukocyte-removing blood product set. 12. The leukocyte-removing blood product set according to claim 11, wherein the blood collecting bag is a vinyl chloride resin bag or a polyolefin bag containing a plasticizer different from the plasticizer contained in the blood component bag.